WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

TSB Funds New Research by CN Bio into Fatty Liver Disease

September 17, 2014

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development of human in vitro models of Non-Alcoholic Fatty Liver Disease (NAFLD).

CN Bio will partner on the award with UK-based CRO Xenogesis Ltd., which specialises in preclinical DMPK, quantitative bioanalysis and expert interpretation.

Within the program, CN Bio will leverage its unique 3D perfused culture platform, LiverChip™, to develop models of fatty liver that are more representative of the human disease than currently available animal models.

NAFLD is very common in overweight and obese patients and can lead to the development of serious liver diseases including Non-Alcoholic Steatohepatitis (NASH), cirrhosis and liver cancer.

CN Bio’s Chief Technical Officer, Dr David Hughes said “Understanding the effects of fat accumulation on liver function will be important for understanding the mechanisms by which NAFLD progresses to more clinically significant liver diseases, identifying biomarkers so that high risk patients can be diagnosed and treated early, and for the development of new drugs to treat NAFLD and NASH.”

Liver disease is currently the fifth leading cause of mortality in the UK. As global obesity rates rise – above the 1.4bn estimated by the World Health Organisation (2008) – the prevalence and health burden of liver disease is projected to increase worldwide.

Category iconBusiness

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023